Dr. Tee SP graduated from University of Malaya with Bachelor of Medicine and Bachelor of Surgery (MBBS) in 1982. He then performed his specialization training in O&G at Seremban General Hospital, University Kebangsaan Malaysia and finally at John Radcliffe Hospital, University of Oxford and was admitted as a member of the Royal College of Obstetricians and Gynaecologists in 1989 and later as a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).
His passion in assisted reproductive technology and fertility treatment led him to pursue his training locally and in National University of Singapore. He qualified with postgraduate Diploma in Reproductive Medicine from the National Population & Family Development Board, Malaysia (LPPKN) in collaboration with Johns Hopkins’ Programme for international Education in O&G, Bachelor of Science in Computing (Hons) from University of Portsmouth, UK and Master of Business Administration from University Tunku Abdul Rahman, Malaysia.
He is one of the pioneer fertility specialists in Malaysia and established Metro IVF Centre in Klang in 1999 and the first IVF pregnancy was delivered in 2000. In 2008, Dr. Tee is one of the key initiators for IVF collaboration between private and public health institutions including Hospital Tengku Ampuan Rahimah, (Metro HTAR IVF Shared Care Programme) and with UiTM (Metro UiTM Private Specialist Centre IVF Shared Care Programme).
With over 20 years of experience in IVF, Dr. Tee has led Metro IVF and it’s group of medical professionals in achieving internationally recognised success rates. The group has since expanded to 7 branches nationwide and was publicly listed in February 2018 on Bursa Malaysia.
Dr. Tee is presently the fertility specialist at Metro IVF and clinical assistant professor at Faculty of Health Science & Medicine at University of Tunku Abdul Rahman (UTAR) and also the treasure and president elect of the Malaysian Society for Assisted Reproductive Technology (MSART).
Dr. Tee SP graduated from University of Malaya with Bachelor of Medicine and Bachelor of Surgery (MBBS) in 1982. He then performed his specialization training in O&G at Seremban General Hospital, University Kebangsaan Malaysia and finally at John Radcliffe Hospital, University of Oxford and was admitted as a member of the Royal College of Obstetricians and Gynaecologists in 1989 and later as a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).
His passion in assisted reproductive technology and fertility treatment led him to pursue his training locally and in National University of Singapore. He qualified with postgraduate Diploma in Reproductive Medicine from the National Population & Family Development Board, Malaysia (LPPKN) in collaboration with Johns Hopkins’ Programme for international Education in O&G, Bachelor of Science in Computing (Hons) from University of Portsmouth, UK and Master of Business Administration from University Tunku Abdul Rahman, Malaysia.
He is one of the pioneer fertility specialists in Malaysia and established Metro IVF Centre in Klang in 1999 and the first IVF pregnancy was delivered in 2000. In 2008, Dr. Tee is one of the key initiators for IVF collaboration between private and public health institutions including Hospital Tengku Ampuan Rahimah, (Metro HTAR IVF Shared Care Programme) and with UiTM (Metro UiTM Private Specialist Centre IVF Shared Care Programme).
With over 20 years of experience in IVF, Dr. Tee has led Metro IVF and it’s group of medical professionals in achieving internationally recognised success rates. The group has since expanded to 7 branches nationwide and was publicly listed in February 2018 on Bursa Malaysia.
Dr. Tee is presently the fertility specialist at Metro IVF and clinical assistant professor at Faculty of Health Science & Medicine at University of Tunku Abdul Rahman (UTAR) and also the treasure and president elect of the Malaysian Society for Assisted Reproductive Technology (MSART).
Dr. Tee SP graduated from University of Malaya with Bachelor of Medicine and Bachelor of Surgery (MBBS) in 1982. He then performed his specialization training in O&G at Seremban General Hospital, University Kebangsaan Malaysia and finally at John Radcliffe Hospital, University of Oxford and was admitted as a member of the Royal College of Obstetricians and Gynaecologists in 1989 and later as a Fellow of the Royal College of Obstetricians and Gynaecologists (FRCOG).
His passion in assisted reproductive technology and fertility treatment led him to pursue his training locally and in National University of Singapore. He qualified with postgraduate Diploma in Reproductive Medicine from the National Population & Family Development Board, Malaysia (LPPKN) in collaboration with Johns Hopkins’ Programme for international Education in O&G, Bachelor of Science in Computing (Hons) from University of Portsmouth, UK and Master of Business Administration from University Tunku Abdul Rahman, Malaysia.
He is one of the pioneer fertility specialists in Malaysia and established Metro IVF Centre in Klang in 1999 and the first IVF pregnancy was delivered in 2000. In 2008, Dr. Tee is one of the key initiators for IVF collaboration between private and public health institutions including Hospital Tengku Ampuan Rahimah, (Metro HTAR IVF Shared Care Programme) and with UiTM (Metro UiTM Private Specialist Centre IVF Shared Care Programme).
With over 20 years of experience in IVF, Dr. Tee has led Metro IVF and it’s group of medical professionals in achieving internationally recognised success rates. The group has since expanded to 7 branches nationwide and was publicly listed in February 2018 on Bursa Malaysia.
Dr. Tee is presently the fertility specialist at Metro IVF and clinical assistant professor at Faculty of Health Science & Medicine at University of Tunku Abdul Rahman (UTAR) and also the treasure and president elect of the Malaysian Society for Assisted Reproductive Technology (MSART).
Pre-Implantation
Genetic Diagnostic / Screening
Pre-Implantation Genetic Diagnostic / Screening
Preimplantation genetic diagnosis (PGD) is a technique used to identify genetic defects in embryos formed before transferring them back into the uterus. It requires an IVF procedure to obtain embryos for PGD evaluation. PGD will help couples at risk of an inherited disorder or mutation gene to prevent the transfer of affected embryos into the uterus. This is to avoid selective pregnancy termination of the affected child. It is considered an alternative to prenatal screening.
PGD can also help those patients who undergo IVF treatment to screen the embryos for chromosome aneuploidies. In this situation, PGD is not used to perform specific prenatal diagnosis, but instead, it is used to screen the embryos for chromosomal abnormalities. It is better referred to as preimplantation genetic screening (PGS). The main indications for PGS include advanced maternal age, history of recurrent miscarriages, and patients who have given birth to genetically abnormal babies. It has also recommended for patients with obstructive and non-obstructive azoospermia because there is an increased risk of fetal abnormalities.
Diseases that can be detected through PGD include:
-
Down’s syndrome (trisomy 21)
-
Edward’s syndrome (trisomy 18)
-
Patau’s syndrome (trisomy 13)
-
Klinefelter’s syndrome (47, XXY)
-
Cystic fibrosis
-
Tay-sachs disease
-
Beta-thalassemia
-
Huntington’s disease
-
Sickle-cell disease
-
Fragile-X syndrome
-
Haemophilia A, etc
PGD is done when an embryo becomes a blastocyst which normally has more than 100 cells five days after fertilization, three or more cells are biopsied from the blastocyst, or it can also be done by taking one or two cells from an 8-cells embryo. Genetic analysis is then performed on the cells that are obtained, to see whether the embryo contains the abnormal gene or chromosome. The analysis is done using Next Generation Sequencing (NGS). NGS is a new technology for comprehensive chromosome testing of IVF embryos or blastocysts. NGS for PGD is replacing other technologies as the predominant method for preimplantation genetic screening (PGS) due to lower cost and reduced errors. In fact, MetroIVF is one of the earliest to use this advanced technology.
The remainder of cell mass from the embryos or blastocyst with the normal gene will be transferred back into the uterus and allowed to implant and developed. Those embryos or blastocyst that are chromosomally or genetically abnormal will not be transferred and allowed to perish. Normally the genetically normal embryos will be cultured until the blastocyst stage and transferred back into the uterus five days after fertilization.